GLP1R and polycystic ovary syndrome: The strengths of this study include having obese women with PCOS and controls who had similar age, weight, BMI and waist circumference; the use of well-established markers to assess atherothrombotic risk; and the first study to assess the effects of treatment with GLP-1 analogue on platelet function in obese women with and without PCOS.